CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to CELG-RI

Neoantigen Dendritic Cell Vaccine

Phase 2
BRISTOL MYERS SQUIBB CO (CELG-RI)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Dec '26
CELG-RIPhase 2

Neoantigen Dendritic Cell Vaccine Phase 2 Est. Readout

Neoantigen Dendritic Cell Vaccine
Dec 2026~
CT.gov
00%
Competitive Landscape

2 competitors in Hepatocellular Carcinoma

View Full Landscape
Drug Information

Target Indication

Hepatocellular Carcinoma

Clinical Trial

NCT04912765

Last updated: 9/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.